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Background: Elevated serum phosphorus (P) levels have been linked to increased morbidity and mortality in
dialysis patients with secondary hyperparathyroidism (SHPT) but may be difficult to control if parathyroid hormone
(PTH) is persistently elevated. We conducted a post hoc analysis of data from an earlier interventional study
(OPTIMA) to explore the relationship between PTH control and serum P.
Methods: The OPTIMA study randomized dialysis patients with intact PTH (iPTH) 300–799 pg/mL to receive
conventional care alone (vitamin D and/or phosphate binders [PB]; n = 184) or a cinacalcet-based regimen (n = 368).
For patients randomized to conventional care, investigators were allowed flexibility in using a non-cinacalcet
regimen (with no specific criteria for vitamin D analogue dosage) to attain KDOQI™ targets for iPTH, P, Ca and
Ca x P. For those assigned to the cinacalcet-based regimen, dosages of cinacalcet, vitamin D sterols, and PB were
optimized over the first 16 weeks of the study, using a predefined treatment algorithm. The present analysis
examined achievement of serum P targets (≤4.5 and ≤5.5 mg/dL) in relation to achievement of iPTH ≤300 pg/mL
during the efficacy assessment phase (EAP; weeks 17–23).
Results: Patients who achieved iPTH≤ 300 pg/mL (or a reduction of ≥30% from baseline) were more likely to
achieve serum P targets than those who did not, regardless of treatment group. Of those who did achieve
iPTH≤ 300 pg/mL, 43% achieved P ≤4.5 mg/dL and 70% achieved P ≤5.5 mg/dL, versus 21% and 46% of those
who did not achieve iPTH≤ 300 pg/mL. Doses of PB tended to be higher in patients not achieving serum P targets.
Patients receiving cinacalcet were more likely to achieve iPTH ≤300 pg/mL than those receiving conventional care
(73% vs 23% of patients). Logistic regression analysis identified lower baseline P, no PB use at baseline and
cinacalcet treatment to be predictors of achieving P ≤4.5 mg/dL during EAP in patients above this threshold
at baseline.
Conclusions: This post hoc analysis found that control of serum P in dialysis patients was better when serum PTH
levels were lowered effectively, regardless of treatment received.
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Chronic kidney disease (CKD) is accompanied by pro-
gressively impaired metabolism of calcium, phosphorus
and vitamin D, eventually leading to secondary hyper-
parathyroidism (SHPT), a clinical syndrome of abnormal
mineral and bone metabolism and extraskeletal calcifica-
tions that is associated with an increased risk of bone
fractures, cardiovascular morbidity and death [1,2].
As elevated serum parathyroid hormone (PTH), phos-
phorus and calcium have all been linked with increased
morbidity and mortality in dialysis (CKD stage 5D) patients
[3-7], the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (NKF-K/DOQI™ [KDOQITM])
in 2003 recommended stringent targets for intact PTH
(iPTH; 150–300 pg/mL), calcium (8.4–9.5 mg/dL) and
phosphorus (3.5–5.5 mg/dL) for this population of patients
[8]. With increasing awareness of the key contribution of
elevated serum phosphorus to vascular calcification and
cardiovascular morbidity [3,4,7,9-11], more recent guide-
lines from the Kidney Disease: Improving Global Out-
comes (KDIGO) group have highlighted the importance of
tight control of serum phosphorus and calcium. KDIGO
suggest that levels as close to normal as possible should be
aimed for in dialysis patients and that the choice of
pharmacological treatment should be influenced by these
parameters [12].
It has long been known that phosphorus loading in ex-
perimental renal failure can contribute to the elevated
PTH levels and parathyroid gland hyperplasia that
characterize SHPT [13]. Much less appreciated is the
concept that SHPT-induced dissolution of bone mineral
may be a significant contributor to the development
of hyperphosphataemia [14], as highlighted in a recent
review [15]. A recent KDOQI commentary also noted
that PTH-induced mobilization of phosphorus from
bone, and potentially other tissues, may contribute to
hyperphosphataemia and that this pathophysiologi-
cal process would not be ameliorated by phosphate bin-
ders [16].
Vitamin D sterols and phosphate binders, together with
dietary phosphate restriction, have traditionally been the
cornerstone of SHPT management. With traditional vita-
min D-based treatments there is a trade-off between con-
trolling PTH on one hand and elevating calcium and
phosphorus on the other hand, making it difficult to
achieve simultaneous control of these parameters. Vita-
min D sterols promote intestinal absorption of calcium
and phosphorus and, in excess, can mobilize calcium
from bone. Thus, excessive calcium loading from
calcium-based phosphate binders and high doses of
vitamin D sterols can promote hypercalcaemia and
hyperphosphataemia, which can necessitate treatment
interruptions [17]. This is reflected in the small propor-
tion of dialysis patients who succeed in achieving andmaintaining the targets recommended by KDOQI for
serum PTH, phosphorus and calcium [18-20].
The calcimimetic agent cinacalcet (MimparaW/SensiparW,
Amgen Inc., Thousand Oaks, CA, USA) has a different
mechanism of PTH-lowering action from vitamin D, with
opposite effects on serum calcium and phosphorus levels.
By enhancing the sensitivity of the parathyroid calcium-
sensing receptors to extracellular calcium, cinacalcet sup-
presses PTH synthesis and secretion [21]. When added to
a conventional treatment regimen, cinacalcet is effective in
lowering serum PTH, phosphorus and calcium levels in
dialysis patients [22-26]. The phase 3 OPTIMA (Open-
Label, Randomized Study Using Cinacalcet to Improve
Achievement of KDOQI Targets in Patients with End-
Stage Renal Disease) study showed that a cinacalcet-based
regimen can allow reduction of vitamin D dosage while
improving mineral metabolism compared to conventional
treatment [26].
We conducted a post hoc analysis of OPTIMA data to
explore the relationship between the control of PTH and
that of serum phosphorus in dialysis patients with
SHPT.
Methods
OPTIMA methodology
A detailed description of the OPTIMA study methods
has been presented elsewhere [26]. Briefly, haemodialysis
and peritoneal dialysis patients with iPTH 300–799 pg/mL,
stratified by baseline serum calcium-phosphorus ion prod-
uct (Ca x P; >55 vs ≤55 mg2/dL2) and baseline vitamin D
use, were randomized to receive either a cinacalcet-based
regimen or conventional care (vitamin D and/or phosphate
binders) in open-label fashion. For patients randomized to
conventional care, investigators were allowed flexibility in
using a non-cinacalcet regimen (with no specific criteria
for vitamin D analogue dosage) to attain KDOQI targets
for iPTH, phosphorus, calcium and Ca x P. For those
assigned to the cinacalcet-based regimen, dosages of cina-
calcet, vitamin D sterols and phosphate binders were opti-
mized over the first 16 weeks, using a predefined
treatment algorithm to achieve KDOQI targets.
The starting dose of cinacalcet 30 mg once daily was
increased stepwise (maximum 180 mg) if iPTH was
>300 pg/mL (biointact PTH >150 pg/mL), unless precluded
by hypocalcaemia (corrected serum calcium <8.0 mg/dL)
or adverse events. Cinacalcet dose was to be reduced if
iPTH was <150 pg/mL and vitamin D sterols were not
being given, or could not be further reduced. If iPTH was
<150 pg/mL and/or calcium and phosphorus exceeded
KDOQI targets, vitamin D dosage was reduced by approxi-
mately 50%, in sequential steps, until a minimum dose was
reached (intravenous calcitriol 0.5 μg, alfacalcidol 1 μg or
paricalcitol 2 μg 3 times per week [TIW] or oral calcitriol
0.25 μg TIW or alfacalcidol 0.25 μg/day). Vitamin D dose
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cinacalcet dose, or in the event of hypocalcaemia not re-
solving with oral calcium supplementation.
Serum PTH, calcium and phosphorus levels were mea-
sured at 2-week intervals throughout the 16-week dose
optimization phase and 7-week efficacy assessment phase
(EAP). The means of these parameters during the EAP
were used to evaluate efficacy. PTH levels measured by
biointact assay were multiplied by 1.95 to convert to
iPTH values [27]. To facilitate comparison of vitamin D
doses, a relative vitamin D dose was calculated by con-
verting dosages into a multiple of the protocol-defined
minimum dose for each vitamin D analogue (see values
above) [26].
For names and addresses of all ethical approval
committees that granted approval for OPTIMA see
Additional file 1.
Present analysis
For the present analysis, we used a relatively low serum
phosphorus cut off of 4.5 mg/dL, in line with the new
recommendations from KDIGO [12], as well as the earl-
ier KDOQI target of 5.5 mg/dL [8]. For iPTH we used a
cut off of 300 pg/mL, the upper limit of the range
recommended by KDOQI [8]: this also falls within the
broader range suggested by KDIGO [12].
The proportion of patients with serum phosphorus
≤ 4.5 or ≤5.5 mg/dL during the EAP was compared for
patients who did, versus those who did not, achieve the
iPTH target of ≤ 300 pg/mL during the EAP. This was
done for both treatment groups combined and addition-
ally by treatment group (conventional care or cinacalcet).
The proportion of patients with serum phosphorus
≤4.5 or ≤5.5 mg/dL during the EAP was also compared
for patients who did, versus those who did not, achieve a
serum PTH reduction ≥30% during the EAP, for both
treatment groups combined and additionally by treat-
ment group.
The following were also evaluated:
 Serum phosphorus, corrected calcium and alkaline
phosphatase activity, at baseline and EAP, and
changes from baseline to EAP, according to PTH
target achievement category at EAP.
 Usage of cinacalcet, vitamin D, calcium- and
aluminium-based phosphate binders and sevelamer,
at baseline and end of EAP, within each PTH and
serum phosphorus target category defined above.
Analysis was performed on the full analysis set (all
randomized patients). A last value carried forward im-
putation (LVCF) method was used for patients who did
not have iPTH, phosphorus or calcium values measured
during the EAP. Patients who still had missing PTH orphosphorus values during the EAP after imputation
(i.e. no post-baseline value) and patients with missing
serum phosphorus values at baseline (N = 13)were
excluded from this analysis. Key analyses were repeated
based on observed data (without imputation). If vitamin
D dose was missing at the end of the EAP due to early
study discontinuation, the vitamin D dose at the time of
discontinuation was used. Likewise, if alkaline phosphat-
ase was missing at the end of the EAP, the last post-
baseline value was carried forward.
Pearson's chi-squared test was used to compare achieve-
ment of serum phosphorus targets by PTH target achieve-
ment category (iPTH≤ versus >300 pg/mL) and magnitude
of PTH reduction (PTH reduction ≥30% versus decrease
<30% or increase during the EAP). The paired t-test was
used to assess changes in serum phosphorus and calcium
and vitamin D doses from baseline to the EAP.
Logistic regression analysis was performed to explore
variables associated with achievement of serum phos-
phorus ≤4.5 mg/dL. Variables considered were serum
phosphorus; iPTH; alkaline phosphatase; use of phos-
phate binders, and vitamin D at baseline, age, country
and randomized treatment. Variables that were found to
be significant (P < 0.05) in univariate analysis were
included in a multivariate analysis, using a stepwise it-
erative procedure.
Results
Patients
Results of OPTIMA are published elsewhere [26]. 184
patients were randomized to conventional care alone and
368 to cinacalcet: demographic characteristics and base-
line laboratory values were similar between the treatment
groups. A total of 82% of patients in the conventional care
group and 76% of those randomized to cinacalcet com-
pleted the EAP. Reasons for early discontinuation
included adverse events (1% conventional care vs 7% cina-
calcet), withdrawal of consent (2% vs 4%), death (3% vs
3%), renal transplantation (3% vs 2%) and other causes
(7% vs 5%) [26]. Cinacalcet was more effective than con-
ventional care in controlling PTH: mean (SD) iPTH levels
decreased from 505 (147) pg/mL at baseline to 264 (168)
pg/mL during the EAP (mean change −46%) in the cina-
calcet arm versus little change in the conventional care
group (from 507 [143] to 519 [281] pg/mL; mean change
+2%). Similarly, mean (SD) serum phosphorus decreased
from 5.5 (1.7) mg/dL at baseline to 5.1 (1.6) mg/dL during
the EAP in the cinacalcet group, but was 5.4 (1.5) mg/dL
at both time points in the conventional care group [26].
Thirteen OPTIMA patients were excluded from the
present analysis on the basis of missing phosphorus and/
or PTH values, leaving a total of 539 patients (n = 357
cinacalcet; n = 182 conventional care). Patients showed
biochemical evidence of high bone turnover, as indicated
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pg/mL and alkaline phosphatase activity of 127 (92)
[median 97] U/L at baseline.Relationship of PTH control to serum phosphorus control
Patients who achieved iPTH≤ 300 pg/mL at the EAP were
more likely to achieve either serum phosphorus≤4.5 or
≤5.5 mg/dL at the EAP than those who did not (P< 0.001
for both phosphorus cut offs) [Table 1]. Among those who
achieved the PTH target, the proportion of patients with
serum phosphorus≤ 4.5 mg/dL increased from 29% at
baseline to 43% at EAP. However, among those who did
not achieve the PTH target, the proportion of patients with
serum phosphorus≤ 4.5 mg/dL remained low (24% at
baseline and 21% at EAP).A similar pattern was seen with
the serum phosphorus ≤5.5 mg/dL cut off: the proportion
of patients within this target increased from 57% to 70%
between baseline and EAP among those who achieved the
PTH target but showed little change from baseline to EAP
in those who did not achieve PTH target (52 vs 46%)
[Table 1]. Results were similar when using observed data,
without imputation of missing values during the EAP.
Patients who failed to achieve the PTH target had little
change in serum phosphorus (p = 0.19), whereas those
who achieved the PTH target had a significant decrease
(P < 0.001). Baseline serum phosphorus levels were simi-
lar in these two subgroups of patients [Table 1; Figure 1].
Figure 1 shows that the decrease in mean serum phos-
phorus in those who achieved the PTH target occurred
shortly after starting treatment and was sustained
throughout the study.
All patients, except for two who were enrolled in error,
had iPTH>300 pg/mL at baseline: 27% and 55% of
patients had serum phosphorus ≤4.5 and ≤5.5 mg/dL,
respectively. Baseline iPTH was slightly higher inTable 1 Serum phosphorus (P) category and mean serum P a
EAP) by iPTH achievement category during EAP
iPTH ≤300 pg/mL at E
Serum P category, no of patients (%)
≤4.5 mg/dL at baseline 88 (29)
≤4.5 mg/dL at EAP 130 (43)*
≤5.5 mg/dL at baseline 172 (57)
≤5.5 mg/dL at EAP 209 (70)*
Serum P mean (SE) absolute values (mg/dL)
Baseline 5.5 (0.10)
EAP 4.9 (0.09)
Change from baseline to EAP −0.6 (0.08)
p-value** <0.001
*P < 0.001 vs subgroup with iPTH> 300 pg/mL at EAP, Pearson chi-squared test. Las
have iPTH or phosphorus values measured during the EAP.
**Paired t-test.
SE: standard error.patients with baseline serum phosphorus > 4.5 mg/dL
versus those with serum phosphorus ≤ 4.5 mg/dL (mean
[SD] 513 [141] vs 482 [144] pg/mL; median 501 vs 457
pg/mL). A similar pattern was seen for the 5.5 mg/dL
cut off (baseline mean [SD] 524 [140] vs 490 [143] pg/
mL; median 507 vs 465 pg/mL).
A total of 41 patients (23%) who received conventional
care and 259 (73%) patients who received cinacalcet
achieved iPTH ≤300 pg/mL (data not shown). Figure 2
shows the proportion of patients achieving serum phos-
phorus targets by achievement of PTH endpoints, sepa-
rated by treatment group. Within each treatment group,
achievement of serum phosphorus targets was more
common in those achieving the PTH target.
Achievement of serum phosphorus targets was also
more common in those who achieved a serum PTH re-
duction ≥30% at EAP (P < 0.001), as shown in Table 2.
Results were similar when using observed data, without
imputation of missing values during the EAP.
Multivariate logistic regression analysis showed that vari-
ables associated with the probability of achieving serum
phosphorus ≤4.5 mg/dL during EAP were baseline serum
phosphorus, baseline iPTH, baseline phosphate binder use
and randomized treatment. Patients with lower baseline
serum phosphorus and iPTH, those not taking phosphate
binders at baseline and those randomized to cinacalcet
were more likely to achieve serum phosphorus ≤4.5 mg/dL
during the EAP. When analysis was restricted to patients
with serum phosphorus> 4.5 mg/dL at baseline, variables
associated with the probability of achieving serum phos-
phorus ≤4.5 mg/dL during EAP were baseline serum phos-
phorus, baseline phosphate binder use and randomized
treatment. Results were similar when analysis was based
on observed serum phosphorus values during the EAP
without imputation, although phosphate binder use was no
longer significant.t baseline and after treatment (efficacy assessment phase;
AP (N=300) iPTH>300 pg/mL at EAP (N= 239)
58 (24)
50 (21)
125 (52)
111 (46)
5.5 (0.10)
5.6 (0.10)
0.1 (0.09)
0.19
t value carried forward imputation (LVCF) was used for patients who did not
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Figure 1 Evolution of serum phosphorus (mean± standard error; SE) by iPTH achievement category (≤ vs > 300 pg/mL) during the
efficacy assessment phase (EAP). Values shown on graph do not exactly match values reported in the text because imputation is used for
calculating values in the text.
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Serum corrected calcium levels were higher in patients
who did not achieve the PTH target, both at baseline
and EAP. These showed a small but statistically signifi-
cant decrease (P < 0.001) in both PTH target achieve-
ment categories (Table 3). In patients who received
conventional care, mean serum calcium was slightly
increased (+0.3 mg/dL) in those with iPTH ≤ 300 pg/mL
and unchanged in those with iPTH>300 pg/mL, at
EAP. However, in those who received cinacalcet, mean
serum calcium was decreased at EAP in both iPTH
achievement categories (−0.7 and −0.8 mg/dL, respect-
ively; data not shown).
Mean (SE) alkaline phosphatase activity at baseline was
125 (5.4) U/L (n=242) in patients who met the PTH target
and 132 (8.8) U/L (n=144) in patients who did not meet
target. Comparison of baseline and EAP values showed a
decrease in both subgroups: mean (SE) -15 (3.4) U/L with
PTH ≤300 pg/mL (n=215) and −11 (5.8) U/L with PTH
>300 pg/mL (n=125) at EAP.
Cinacalcet, vitamin D and phosphate binders
As reported previously [26], approximately two-thirds of
patients in each treatment group were receiving vitamin
D sterols at baseline and approximately 90% were receiv-
ing phosphate binders. Use of vitamin D increased in
the conventional care group (from 66% of patients at
baseline to 81% of patients at the end of the study),but showed little change in the cinacalcet group (from
68% to 73% of patients). Among patients receiving vita-
min D at baseline, the mean relative dose decreased by
22% in cinacalcet-treated patients from baseline to week
23, but was virtually unchanged (3% increase) in those
receiving conventional care. Cinacalcet-treated patients
also required less sevelamer and aluminum-based bin-
ders but more calcium-based binders [26].
Table 4 shows mean doses of cinacalcet, vitamin D
(relative doses) and phosphate binders at baseline and
EAP by iPTH and serum phosphorus target category.
Within both PTH strata, doses of cinacalcet and
phosphate binders tended to be higher in patients
who were failing to meet serum phosphorus targets,
compared with those who did achieve these targets
[Table 4].
The relationship of vitamin D use to serum phos-
phorus achievement was less consistent, but patients
who were failing to meet the PTH target were receiving
higher vitamin D doses [Table 4]. There was a significant
increase in mean relative vitamin D dose, from 1.6 at
baseline to 1.8 at the end of the EAP, in patients not
achieving the iPTH target (mean change 0.2; p = 0.04).
In those achieving the iPTH target, mean relative vita-
min D dose decreased, from 1.6 to 1.4, although this
change was not statistically significant (mean change
−0.1; p = 0.18). Figure 3 shows a divergence in mean
relative vitamin D dose between the two PTH target
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Figure 2 Proportion of patients with serum phosphorus (P) (a) ≤4.5 and (b) ≤5.5 mg/dL by iPTH achievement category after treatment
with cinacalcet or conventional care. Figures show % of patients with P control (≤4.5 or ≤5.5 mg/dL) within each PTH achievement category
during the efficacy assessment phase (EAP).
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be noted that patient numbers decreased between base-
line and EAP.Table 2 Serum phosphorus (P) category at baseline and after
magnitude of PTH reduction at EAP
PTH reduction ≥30% at EAP (N
P ≤4.5 mg/dL at baseline, n (%) 90 (28)
P ≤4.5 mg/dL at EAP 131 (40)*
P ≤5.5 mg/dL at baseline 182 (56)
P ≤5.5 mg/dL at EAP 222 (68)*
*P < 0.001 vs subgroup with PTH reduction <30% or increase at EAP, Pearson chi-sq
who did not have iPTH or phosphorus values measured during the EAP.Discussion
The present post hoc analysis of data from OPTIMA [26]
showed that serum phosphorus was better controlledtreatment (efficacy assessment phase; EAP) by
=326) PTH reduction <30% or increase at EAP (N= 213)
56 (26)
49 (23)
115 (54)
98 (46)
uared test. Last value carried forward imputation (LVCF) was used for patients
Table 3 Mean (SE) corrected serum calcium at baseline and after treatment (efficacy assessment phase; EAP) by iPTH
target achievement during EAP
Calcium, mg/dL iPTH ≤300 pg/mL at EAP (N= 300) iPTH>300 pg/mL at EAP (N= 239)
Baseline 9.6 (0.04) [298] 9.8 (0.05) [236]
EAP 9.1 (0.05) [300] 9.5 (0.05) [239]
Change from baseline to EAP −0.5 (0.05) [298] −0.3 (0.05) [236]
p-value* <0.001 <0.001
*Paired t-test. Last value carried forward imputation (LVCF) was used for patients who did not have iPTH or calcium values measured during the EAP.
SE: standard error.
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received cinacalcet or standard treatment. However, those
receiving cinacalcet (two-thirds of patients) were more
likely to achieve iPTH ≤300 pg/mL than those receiving
conventional treatment (73% vs 23% of patients). In theTable 4 Usage and dose of cinacalcet, phosphate binders (mg
subgroup at baseline and the end of the efficacy assessment
a. Target P ≤4.5 mg/dL
Mean (SE) dose [% of patients] iPTH ≤300 pg/mL**
P ≤4.5 mg/dL
BASELINE -
Ca-based binders -
Sevelamer -
Vitamin D -
Al-based binders -
EAP N= 130
Cinacalcet 44 (4) [79]
Ca-based binders 1844 (197) [63]
Sevelamer 4192 (428) [33]
Vitamin D 1.3 (0.1) [70]
Al-based binders 2876 (605) [8]
b. Target P ≤5.5 mg/dL
Mean(SE) dose [% of patients] iPTH ≤300 pg/mL**
P ≤5.5 mg/dL
BASELINE -
Ca-based binders -
Sevelamer -
Vitamin D -
Al-based binders -
EAP N= 209
Cinacalcet 46 (3) [83]
Ca-based binders 1975 (156) [64]
Sevelamer 4454 (279) [40]
Vitamin D 1.4 (0.1) [74]
Al-based binders 2462 (410) [7]
*Relative dose: dosage is based on conversion of each dose a patient received into
calcitriol = 0.5 μg 3 times per week (TIW), IV alfacalcidol = 1 μg TIW, IV paricalcitol = 2
Patients not receiving vitamin D at a timepoint are counted as having a zero dose a
based on those actually receiving these agents.
**Patients were required to have iPTH 300 – 799 pg/mL at baseline but two patient
patients are not shown separately.
SE: standard error.subgroup of patients who achieved iPTH ≤300 pg/mL at
EAP, serum phosphorus levels decreased significantly and
more than 40% achieved serum phosphorus≤ 4.5 mg/dL.
The decrease in serum phosphorus occurred shortly after
starting treatment and was sustained throughout the/day) and vitamin D (relative doses)* by PTH and P
phase (EAP)
iPTH>300 pg/mL
P>4.5 mg/dL P ≤4.5 mg/dL P >4.5 mg/dL
- N = 146 N= 393
- 1989 (215) [41] 1883 (121) [47]
- 4137 (297) [48] 4876 (156) [55]
- 1.5 (0.1) [70] 1.6 (0.1) [67]
- 1874 (222) [18] 2450 (188) [20]
N= 170 N= 50 N= 189
54 (4) [84] 81 (15) [33] 96 (8) [34]
2331 (202) [71] 1888 (234) [36] 2218 (267) [48]
4973 (250) [53] 4345 (480) [50] 4830 (256) [63]
1.6 (0.2) [77] 2.0 (0.3) [83] 1.8 (0.1) [78]
2335 (319) [16] 2469 (557) [19] 2837 (369) [18]
iPTH>300 pg/mL
P >5.5 mg/dL P ≤5.5 mg/dL P >5.5 mg/dL
- N = 297 N= 242
- 1880 (142) [45] 1944 (159) [45]
- 4434 (195) [48] 4960 (196) [58]
- 1.6 (0.1) [70] 1.5 (0.1) [65]
- 1995 (199) [14] 2518 (215) [25]
N= 91 N= 111 N= 128
60 (6) [81] 85 (10) [31] 99 (10) [36]
2458 (298) [76] 2079 (313) [47] 2238 (326) [44]
5168 (344) [57] 4175 (347) [51] 5103 (292) [68]
1.6 (0.3) [74] 2.1 (0.2) [82] 1.6 (0.2) [77]
2463 (384) [24] 2859 (519) [12] 2709 (390) [23]
a multiple of the defined minimum dose for a particular sterol: IV
μg TIW, oral calcitriol = 0.25 μg TIW, oral alfacalcidol = 0.25 μg once daily.
t that timepoint. For Ca-or Aluminium-based P binders and sevelamer, dose is
s with PTH <300 pg/mL were enrolled in error. For simplicity, data for these
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Figure 3 Evolution of relative vitamin D dose (mean± standard error; SE) by iPTH achievement category (≤ vs >300 pg/mL) during the
efficacy assessment phase (EAP). Note that this shows vitamin D dose over time for all patients still on study. If a patient is not receiving
vitamin D at a particular timepoint their relative dose will be zero and will be included as such in the calculation of mean relative dose. See text
for explanation of mean relative dose. Values shown on graph do not exactly match values reported in the text because imputation is used for
calculating values in the text.
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PTH target did not show any improvement in serum
phosphorus between baseline and EAP, either in terms of
mean absolute levels or the proportion of patients within
serum phosphorus targets. Only 21% had serum phos-
phorus ≤4.5 mg/dL at EAP.
Achievement of serum phosphorus targets was also
more common in those who had a serum PTH reduc-
tion ≥30% at EAP. Logistic regression analysis identified
lower baseline serum phosphorus, no phosphate binder
use at baseline and cinacalcet treatment to be predictors
of achieving serum phosphorus ≤4.5 mg/dL during EAP
in patients who were above this threshold at baseline.
Improvement in serum phosphorus control was not
related to increased phosphate binder usage overall. In-
deed, usage of phosphate binders tended to be higher in
patients who were failing to meet serum phosphorus tar-
gets [Table 4]. There was a significant increase in relative
vitamin D dose in patients with uncontrolled PTH but
this was not accompanied by a significant increase in
serum phosphorus. On the other hand, a significant de-
crease in serum phosphorus was seen in those with con-
trolled PTH, although a significant decrease in relative
vitamin D dose was not seen in this subgroup. These
findings suggest that changes in vitamin D andphosphate binders are less important than changes in
PTH in this setting.
Serum corrected calcium levels were higher in
patients who did not achieve the PTH target, both at
baseline and EAP. It could be argued that a less sup-
pressible PTH is accompanied by a higher serum cal-
cium set-point and hence a higher serum calcium
level. Alternatively, less suppressible PTH might have
induced clinicians to use higher doses of vitamin D,
with a consequent increase in serum calcium. Patients
showed biochemical evidence of high bone turnover
at baseline, as indicated by their elevated PTH and al-
kaline phosphatase values. Alkaline phosphatase activ-
ity decreased by a similar amount in the two PTH
achievement categories.
As this is a post-hoc analysis, it is difficult to establish
causality for the serum phosphorus changes observed
in OPTIMA. There were no checks for dietary control
and compliance in the study and nutritional markers
were not studied. Thus, we cannot exclude the possibil-
ity that improved dietary compliance could have played
a part in the serum phosphorus reduction in some
patients. Bone biopsies were not performed in OPTIMA
and bone turnover markers other than PTH and alkaline
phosphatase were not studied. Moreover, as analyses
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were not standardized.
PTH is known to mobilize calcium and phosphorus
from bone [14] and evidence to support the hypothesis
that improved PTH control leads to improved serum
phosphorus control is accumulating. Substantial de-
creases in serum phosphorus levels have been observed
in patients who undergo parathyroidectomy for
advanced SHPT [28-30]. It is common to see decreases
in the early postoperative period, with sustained im-
provement in phosphorus control thereafter. In addition,
it has recently been shown that direct infusion of PTH
leads to a significant rise in serum phosphorus in dialysis
patients, especially in those with high-turnover bone dis-
ease [31]. This increase can be observed after several
hours of infusion and during the fasting state, support-
ing a primary role for PTH-induced bone resorption as
the mechanism for the increased phosphorus levels.
Moreover, analysis of PTH evolution over time also
shows that increases in PTH are associated with an in-
crease in serum phosphorus and vice versa [32]. These
findings raise the question as to whether increased
serum phosphorus levels are stimulating parathyroid
gland function, or whether hyperparathyroidism is lead-
ing to worsened phosphorus control via increased bone
resorption. It is likely that both of these pathophysio-
logical mechanisms operate in a vicious cycle in end-
stage renal disease. Indeed, recent studies have docu-
mented the efficacy of cinacalcet in reducing increased
total and bone-specific alkaline phosphatase [33].
The lower serum phosphorus cut off that we explored
(≤4.5 mg/dL) is in line with new recommendations from
KDIGO to aim for near-normal serum phosphorus levels
in dialysis patients [12]. Although KDIGO have recom-
mended a lowering of the phosphorus target range, they
have also relaxed the PTH target range [12] for a variety
of reasons, including the observation that a significant
proportion of patients with iPTH in the 150–300 pg/mL
range have low-turnover bone disease [34]. A recent co-
hort study in 22,937 dialysis patients showed that con-
sistent control of markers of bone metabolism and
disease within KDOQI targets is a strong predictor of
survival in this population [19]. Compared with those
who achieved target for three variables (PTH, phos-
phorus and calcium), the risk of death was 51%, 35–39%
and 15–21% higher in patients who achieved none, one
and two of these targets. For each marker, maintaining
within target for one calendar quarter or less was asso-
ciated with a higher mortality risk than achieving control
for four quarters: 16% higher for calcium and 34% for
PTH, rising to 62% higher for phosphorus [19]. Other
data published since the KDOQI guidelines have shown
improved outcomes in dialysis patients if PTH is con-
trolled [35-37]. For instance, a case control study basedon the US Renal Data System found a 32% reduction in
hip fracture risk after parathyroidectomy [35]. Coronary
artery calcification score in dialysis patients was also
found to be independently associated with iPTH levels
in the ADVANCE study [38]. In the CORES study in
16,173 patients, both elevated and low serum levels of
calcium, phosphorus and PTH were associated with
increased mortality [36].
Conclusions
Our findings suggest that in dialysis patients with bio-
chemical evidence of high-turnover bone disease, serum
phosphorus control may be linked to PTH control: con-
trol of serum phosphorus was more difficult in patients
with poorly controlled PTH. Further research is war-
ranted to clarify these findings.
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